This statistical model forecasts the progression of Alzheimer’s disease several years in advance, using only the current medical data of a patient at an early stage of the disease. With testing on over 96,000 cases from 4,600 patients in 4 continents, the accuracy of this model is unmatched.
Not only is AD Course Map unbiased with regard to sex and geographical origin, but it is also robust to missing data. This allows us to make more informed and timely decisions about the best time to test new treatments in patients. In fact, the team has shown that using AD Course Map can decrease the required sample size by up to 50% in clinical trials!
At its core, AD Course Map will help us care for patients earlier and better, by anticipating disease progression and empowering both patients and care teams with the information they need to make the best decisions.
Read full article here.
28.03.2023
New tool in the fight against Alzheimer’s disease
Don’t miss the latest article by the team of PR[AI]RIE chair, Stanley Durrlemann, published in the Nature Communications. It presents a new powerful tool in the fight against Alzheimer's disease: AD Course Map.
